Can PRP Heal a Torn Meniscus? What the Research Shows

PRP can reduce pain and improve function in people with meniscus tears, but calling it a “heal” depends heavily on the type of tear, the treatment context, and how you define healing. The strongest evidence supports PRP as an add-on to surgical meniscus repair, where it roughly cuts the failure rate in half compared to surgery alone. As a standalone injection for degenerative tears, PRP reliably improves symptoms in the short term, yet imaging studies show the tear itself often persists. The gap between feeling better and actual tissue repair is where much of the confusion around PRP and meniscus injuries lives.

Why Meniscus Tears Are Stubborn

The meniscus is a crescent-shaped piece of cartilage that sits between the thighbone and shinbone, acting as a shock absorber. Its healing ability is not uniform. The outer third has a decent blood supply and can repair itself reasonably well when damaged. The inner two-thirds, however, get almost no direct blood flow. Without blood delivering the cells and nutrients that drive tissue repair, tears in this inner zone tend to stay torn unless something intervenes.

This distinction matters enormously for any discussion of PRP. A study comparing outcomes of meniscal repairs across these vascular zones found that tears in the well-vascularized outer zone achieved better function, faster recovery, and fewer complications, while tears in the avascular inner zone carried a higher risk of needing reoperation.¹ If PRP is going to help, it needs to overcome this basic biological limitation, and that is a tall order for a single injection.

What PRP Actually Does Inside the Joint

PRP is made by drawing your own blood, spinning it in a centrifuge to concentrate the platelets, and injecting that concentrate into or around the injured tissue. Platelets are best known for clotting, but they also release a cocktail of growth factors when activated. These signaling molecules promote new blood vessel formation, attract repair cells to the injury site, and stimulate the production of the structural matrix that cartilage is made of.² Lab studies have confirmed that specific growth factors found in platelet concentrates do stimulate meniscus cells to migrate, multiply, and build new tissue.³

The theory is appealing: flood a poorly vascularized tear with the growth factors it would normally never see, and kickstart healing. The problem is that what works in a dish of cells does not always translate to an intact human knee, where the mechanical environment is harsh and the growth factors get diluted in joint fluid within hours. The research question is whether enough of a biological signal gets through to make a measurable clinical difference.

PRP Injections Without Surgery

For people with degenerative meniscus tears, the kind that develop gradually in middle age rather than from a sports injury, PRP injections are sometimes offered as a non-surgical option. The evidence here is real but uneven. A systematic review of studies on degenerative tears treated with PRP alone found that four out of five studies reported significant pain improvement from baseline to the final follow-up. Functional scores also improved across most studies, and return to sport occurred in roughly 60% to 100% of patients depending on the study.⁴

Individual studies reinforce this trend. One trial of intrameniscal PRP injections for degenerative tears found that a commonly used knee function score improved from about 57 out of 100 before treatment to roughly 73 afterward.⁵ Another study focusing on moderate-grade degenerative meniscus lesions reported significant improvements across multiple clinical scoring systems after PRP injections.⁶

The catch is what happens on imaging. MRI scans tell a less optimistic story. Across the studies that looked at structural changes, complete healing of the tear on MRI occurred in anywhere from 0% to 44% of patients, and partial healing in 0% to 40%.⁴ That wide range tells you the imaging outcomes are inconsistent. Some people show structural improvement; many do not, even though they feel better. This disconnect between symptom relief and tissue repair is one of the most important things to understand about PRP for meniscus tears. Feeling less pain does not necessarily mean the tear has healed.

PRP Added to Surgical Repair

The picture looks considerably stronger when PRP is used to augment arthroscopic meniscus repair rather than replace it. This is where the data is most encouraging. A meta-analysis pooling results from comparative studies found that meniscal repairs augmented with PRP had a failure rate of about 11%, compared to 27% in repairs without PRP.⁷ That is a large and statistically meaningful difference. A more recent systematic review and meta-analysis confirmed this direction, finding consistently lower failure rates in the PRP augmentation group.⁸

Why might PRP work better as a surgical companion than as a standalone treatment? One likely reason is that surgery already creates the conditions for healing. The surgeon trims damaged tissue, brings torn edges together with sutures, and sometimes stimulates bleeding to bring repair cells to the area. PRP applied at that moment gives those repair cells an additional boost of growth factors right when they can use them most. On its own, PRP is trying to coax healing in tissue that may not have the structural alignment or blood supply to respond.

The Placebo Question

One of the trickiest aspects of evaluating PRP is separating genuine biological effects from placebo response. Injection therapies in general tend to produce strong placebo effects in knee pain, partly because the ritual of treatment (the clinical visit, the injection itself, the expectation of improvement) can reduce perceived pain independent of what is in the syringe.

The most rigorous test of PRP for knee conditions came from the RESTORE trial, a large randomized study that compared PRP injections to saline placebo in patients with knee osteoarthritis. After twelve months, PRP did not outperform placebo on pain, cartilage volume, or almost any secondary outcome measured.⁹ The RESTORE trial studied osteoarthritis, not isolated meniscus tears, so the findings do not directly apply to someone with a meniscal injury and an otherwise healthy knee. But the trial is a sobering reminder that improvements seen in uncontrolled PRP studies may partly reflect what any injection could achieve. Until similarly rigorous sham-controlled trials are conducted specifically for meniscus tears, there is room for skepticism about how much of the benefit is truly from the platelets.

Short-Term Relief Versus Lasting Change

Even in studies that show positive results, the benefit of PRP tends to be most obvious in the first few months. A narrative review of PRP for meniscus injuries noted that at follow-up periods under one year, PRP produced significant improvements in knee symptoms and daily activity. At longer follow-up, however, the differences between PRP and non-PRP groups on pain scores and functional measures were no longer significant.² This pattern suggests PRP may be offering a window of accelerated improvement rather than a permanent fix, at least for non-surgical applications.

For surgical augmentation the story seems better, since the lower failure rates measured in those studies do represent lasting structural outcomes (the repair either holds or it does not). But for injection-only approaches, the fading benefit over time is something patients should know about going in. If PRP helps you through a period of rehabilitation and physical therapy, that might still be valuable. Just do not expect a single round of injections to permanently resolve a meniscal problem.

Who Is a Good Candidate

Not every torn meniscus is a good match for PRP. The studies on non-surgical PRP injections have been conducted mostly on a specific patient profile: middle-aged adults (average age around 48) with chronic, degenerative, or intrasubstance tears and without severe arthritis.⁴ Five of the six studies in one systematic review specifically excluded patients with advanced degenerative joint disease. If your knee already has significant cartilage loss from osteoarthritis, the data supporting PRP for your meniscus is thin.

Tear location matters as well. The vascular zone determines how much healing capacity the tissue has at baseline, and PRP is more likely to tip the scales in areas that have some existing blood supply. A completely avascular inner-zone tear in a knee with advanced wear may simply lack the biological infrastructure to respond, no matter how many growth factors are delivered.

Age also plays a role, though not in the direction people sometimes assume. Older patients with degenerative tears are the ones most studied for non-surgical PRP. Younger patients with acute traumatic tears are more likely to be candidates for surgical repair, and PRP augmentation at the time of that surgery has the strongest evidence behind it. The worst scenario for PRP is probably a large, complex tear in the avascular zone of an older knee with significant arthritis, where the biological environment is hostile and the structural problem is beyond what growth factors can address.

Safety Profile

One area where PRP performs well is safety. Because the product comes from your own blood, the risk of allergic reaction or disease transmission is essentially zero. A meta-analysis of randomized controlled trials found no statistically significant difference in complication rates between PRP and control groups.¹⁰ The most common side effects are temporary: mild pain at the injection site, some swelling, and occasional stiffness for a few days afterward. Serious adverse events are rare in the published literature.

This favorable safety profile is part of why PRP has gained popularity even ahead of the evidence. When the downside risk is low, both patients and clinicians are more willing to try something that might help, even if the proof is not yet airtight. That is a reasonable individual decision, but it is different from saying the science clearly shows PRP heals meniscus tears.

Why Not All PRP Is the Same

One of the muddiest aspects of PRP research is that “PRP” is not a single standardized product. The concentration of platelets, the volume injected, the number of injections, and whether white blood cells are included all vary between clinics and between studies. This makes comparing results across trials genuinely difficult.

The white blood cell question is particularly interesting. Some preparations deliberately include leukocytes (leukocyte-rich PRP), while others filter them out (leukocyte-poor PRP). The rationale for including white blood cells is that the inflammatory phase they trigger may be necessary for tissue repair. Macrophages in particular can shift from a pro-inflammatory state to an anti-inflammatory, pro-healing state, and this switch may be important for regeneration.¹¹ The counterargument is that too much inflammation in a joint is harmful. There is no consensus yet on which formulation works best for meniscus injuries, which means two patients getting “PRP” at different clinics may be receiving substantially different treatments.

Injection technique adds another variable. Some providers inject PRP into the joint space (intra-articular), while others use ultrasound guidance to place the injection directly into the meniscus tissue (intrameniscal). A recent study compared serial ultrasound-guided perimeniscal injections against a single intra-operative intra-articular injection, but acknowledged that the protocols differed in so many ways simultaneously that isolating the independent effect of PRP itself was not possible.¹² Until standardized protocols emerge and are tested head-to-head, the “best” way to use PRP for meniscus injuries remains an open question.

The Cost and Insurance Reality

PRP injections are rarely covered by insurance for meniscus tears. Most insurers consider the treatment experimental or investigational for this indication, which means you pay out of pocket. A single injection typically runs several hundred dollars, and some protocols call for multiple injections spaced weeks apart. The total cost can reach into the low thousands.

Whether that cost is justified depends partly on the alternative. For a degenerative tear in a middle-aged knee, the main surgical option has historically been partial meniscectomy, which involves trimming away the damaged portion. That procedure relieves symptoms in many patients, but it also removes tissue the knee needs for long-term shock absorption, and research over the past decade has raised serious questions about its long-term value for degenerative tears. One study found that physical therapy combined with orthobiological treatments including PRP was more effective than partial meniscectomy alone for degenerative tears in the context of knee osteoarthritis.¹³ If PRP can help someone avoid or delay meniscus removal, the long-term value of preserving that tissue could outweigh the upfront injection cost. But this remains speculative until longer-term comparative data are available.

What a Reasonable Expectation Looks Like

If you are considering PRP for a meniscus tear, the honest summary of the evidence is this: PRP is not a magic fix that regrows torn cartilage. When used alongside surgical repair, it meaningfully improves the odds that the repair will hold. When used as a standalone injection for degenerative tears, it often reduces pain and improves function in the short term, but the structural tear frequently persists on imaging and the benefits may fade over time. The treatment is safe, but unregulated in terms of preparation and dosing, which means quality varies between providers.

The strongest candidates are people with repairable tears who can benefit from surgical augmentation, or people with moderate degenerative tears who want to try a conservative approach before considering surgery. People with advanced arthritis, large complex tears, or tears in the avascular zone should temper their expectations. And anyone considering PRP should ask their provider specific questions about the formulation being used, the injection technique, and how many sessions are planned, since these details are not standardized and can influence outcomes.

Where the Research Goes From Here

The biggest gap in the PRP-meniscus literature is the lack of large, sham-controlled trials that specifically target meniscus tears. Most injection studies compare PRP to baseline (no treatment) rather than to a placebo injection, which leaves the door open for placebo effects to inflate the results. The surgical augmentation studies are stronger in design because the comparison is surgery with and without PRP, but even those could benefit from blinding. Researchers are also working on standardizing PRP formulations so that studies can be compared more meaningfully. A trial using one platelet concentration, injection route, and dosing schedule cannot be directly compared to a trial using different parameters for all three. Until that standardization happens, the field will keep producing evidence that points in a generally positive direction without delivering the definitive answers patients want.